Safety of a modified environmental rush immunotherapy protocol in the pediatric population
Christopher H Chu1, Jason W Caldwell1, Leslie M Cristiano1
1Section of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest Baptist Health, Winston Salem, North Carolina.
Abstract
No abstract available in PubMed .
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
17
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
17
Pharmacokinetics in Pediatric Patients: Drug Metabolism
24
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
24
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
15
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
15


